Papzimeos
Payments companies reported to CMS as associated with Papzimeos. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Papzimeos, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Papzimeos
These are the largest totals companies reported as associated with Papzimeos. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Clark Rosen | San Francisco, CA | Otolaryngology | $9,811.69 |
| Aaron Friedman | Cincinnati, OH | Otolaryngology | $7,722.67 |
| Albert Merati | Seattle, WA | Otolaryngology | $7,399.36 |
| Adam Klein | Atlanta, GA | Otolaryngology | $5,397.36 |
| Craig Derkay | Norfolk, VA | Otolaryngology | $5,138.81 |
| Milan Amin | New York, NY | Otolaryngology | $4,618.12 |
| Margaret Huston | Creve Coeur, MO | Otolaryngology | $4,562.26 |
| Geoffrey Young | Miami, FL | Surgical Oncology | $4,500.00 |
| Sara Pai | New Haven, CT | Otolaryngology | $3,679.08 |
| Herbert Sims | Chicago, IL | Otolaryngology | $3,257.17 |
Prescribed Papzimeos?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.